Section 182 of the Trade Act of 1974, known as the “Special 301” provisions, requires the United States Trade Representative to identify countries that deny adequate and effective intellectual property protections or fair and equitable market access to U.S. persons who rely on IP protection. As part of the 2021 Special 301 Review process conducted by USTR, Justin Pine, J.D., Senior Director of International Affairs, prepared BIO’s formal submission to USTR and the interagency Special 301 subcommittee highlighting the IP issues facing our members in key markets around the world.
In addition to addressing systemic IP challenges abroad, BIO’s 2021 Special 301 Review Submission highlights how IP is critical to supporting BIO’s Vision, Mission, and Purpose as an enabler of biotech innovation. This year’s submission also illustrates the critical role of IP as a tool to defeat COVID-19 and as a driver of economic growth and recovery in the post-pandemic world.
BIO submitted these comments in response to the United States Patent and Trademark Office’s May 10, 2024, Notice of Proposed Rulemaking regarding Terminal Disclaimer Practice to Obviate Nonstatutory Double Patenting.
On behalf of its member organizations, Biotechnology Innovation Organization (“BIO”) respectfully submits this Comment in response to the United States Patent and Trademark Office’s (the “Patent Office” or “PTO”) February 13, 2024 Request for…
The meeting of global trade ministers at the World Trade Organization’s 13th Ministerial Conference in Abu Dhabi offers an important opportunity to build on and strengthen the open and rules-based international trading system to support better…
Section 182 of the Trade Act of 1974, known as the “Special 301” provisions, requires the United States Trade Representative to identify countries that deny adequate and effective intellectual property protections or fair and equitable market access to U.S. persons who rely on IP protection. As part of the 2021 Special 301 Review process conducted by USTR, Justin Pine, J.D., Senior Director of International Affairs, prepared BIO’s formal submission to USTR and the interagency Special 301 subcommittee highlighting the IP issues facing our members in key markets around the world.
In addition to addressing systemic IP challenges abroad, BIO’s 2021 Special 301 Review Submission highlights how IP is critical to supporting BIO’s Vision, Mission, and Purpose as an enabler of biotech innovation. This year’s submission also illustrates the critical role of IP as a tool to defeat COVID-19 and as a driver of economic growth and recovery in the post-pandemic world.